10:45 AM EST, 11/05/2024 (MT Newswires) -- Tevogen Bio Holdings ( TVGN ) said Tuesday it's artificial intelligence initiative Tevogen.AI has launched a partnership with Microsoft ( MSFT ) to investigate potential treatments for human papilloma virus.

Tevogen said it has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T-cell targets to choose for a trial for TVGN 920, which will be its first oncology product.

"By leveraging Microsoft's ( MSFT ) cutting-edge AI and cloud technologies, we're able to accelerate our target identification and pre-clinical processes in ways that weren't previously possible," said Tevogen.AI Chief Information Officer and Head Mittul Mehta.

Financial details about the project weren't provided.

Price: 1.91, Change: -0.05, Percent Change: -2.81